INTRODUCTION {#s1}
============

Lung cancer is the most common cause of cancer death, claiming 1.59 million lives in 2012 worldwide \[[@R1]\]. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers and chemotherapy is one of the key components in the treatment protocol \[[@R2]\]. Although there is strong evidence to show that standard chemotherapy in addition to best supportive care can prolong overall survival and improve the quality of life \[[@R3]\], prognosis remains poor, especially in patients with advanced NSCLC. The median overall survival and the 5-year survival rate is only 1 year and 3.5%, respectively \[[@R4]\].

A large proportion of NSCLC patients have sensitizing mutations in exon 19 or 21 (approximately 45 and 40% of patients, respectively) which activate the tyrosine kinase domain in epidermal growth factor receptors (EGFR). The discovery of EGFR tyrosine kinase inhibitors (TKI) was regarded as a landmark finding in the treatment of lung cancer \[[@R5]--[@R8]\]. Targeted EGFR-TKI first-line treatment of sensitizing *EGFR* mutations results in longer PFS, improved health-related quality of life and decreased treatment-related severe side effects when compared with those who received standard chemotherapy \[[@R6], [@R7], [@R9]--[@R13]\]. Many clinical guidelines therefore recommend that all patients with sensitizing *EGFR* mutations receive first-line treatment with these drugs \[[@R14]--[@R19]\], in addition to all patients with advanced or metastatic NSCLC \[[@R2], [@R20]\].

Despite benefits in using EGFR-TKIs for first-line therapy in all sensitizing mutations, in resource limited situations, targeted screening may be appropriate \[[@R21]\]. Knowledge on the prevalence of *EGFR* mutations in different patient subgroups could therefore inform policy and testing strategies. Existing individual studies may not be informative for estimating prevalence because of small sample sizes in case-series or non-representative sample selection. The mutation prevalence reported in whole study or sub-group populations also varies dramatically in published studies \[[@R22]--[@R30]\] and the reported prevalence rates are therefore currently inappropriate for applying to other populations. In order to obtain a more precise estimate of *EGFR* mutation prevalence in NSCLC patients and patient subgroups, we conducted this systematic review and meta-analysis.

RESULTS {#s2}
=======

We identified 6,221 potentially eligible citations, of which 456 studies were finally included (Figure [1](#F1){ref-type="fig"}). The majority of included studies were case series (56.6%) and cohort studies (33.2%). Sixty-six percent of the studies were conducted in Asian countries. The median sample size was 103, ranging from 11 to 18,246. Median participant age was 63 years, 56.1% were males and 57.0% were past or current smokers. Histology was reported in 45.0% of studies and 73.3% of patients had adenocarcinoma. *EGFR* exon 19 or 21 mutation was assessed in 89.3% of the studies (see [Table A.1](#SD2){ref-type="supplementary-material"} for study characteristics).

![The flow chart of study selection\
This figure provides detailed information for the study inclusion and exclusion.](oncotarget-07-78985-g001){#F1}

In total, 30,466 patients with an *EGFR* mutation were reported among 115,815 patients with NSCLC. The overall pooled prevalence of all *EGFR* mutations and *EGFR* exon 19 or 21 mutations was 32.3% (95% CI: 30.9% to 33.7%) and 32.2% (95% CI: 29.6% to 34.8%), respectively (Table [1](#T1){ref-type="table"}). *EGFR* mutation prevalence varied by study location and ethnicity: Asia had the highest prevalence (38.4%, 95% CI: 36.5% to 40.3%) \[China: 38.4% (95% CI: 35.7% to 41.1%); Japan: 36.6% (95% CI: 33.2% to 40.0%); Korea 32.4% (95% CI: 28.0% to 36.8%)\], followed by North and South America (24.4%, 95% CI: 22.1% to 26.8%) and Europe (14.1%, 95% CI: 12.7% to 15.5%). The prevalence among different ethnicities were similar to study locations, with the prevalence of 38.8% (95% CI: 36.8% to 40.8%) in Asian populations, 17.4% (95% CI: 15.8% to 18.9%) in Caucasians, 17.2% (95% CI: 5.7% to 28.8%) in African-Americans, and 27.0% (95% CI: 22.6% to 31.4%) in mixed populations.

###### The pooled prevalence of *EGFR* mutation in different NSCLC patient subgroups

  Group variables                                                   No. of studies   Mutation prevalence, % (95%CI)   Tests of heterogeneity   
  ----------------------------------------------------------------- ---------------- -------------------------------- ------------------------ ------
  All studies                                                       456              32.3(30.9 to 33.7)               \<0.001                  97.3
  Exon mutation location                                                                                                                       
   Exon 19                                                          343              16.7(15.8 to 17.5)               \<0.001                  93.2
   Exon 21                                                          330              12.3(11.6 to 13.0)               \<0.001                  92.7
   Exon 19 or 21                                                    95               32.2(29.6 to 34.8)               \<0.001                  95.5
   Exon 18                                                          90               1.2(1.0 to 1.4)                  \<0.001                  48.6
   Exon 20                                                          93               1.7(1.4 to 2.0)                  \<0.001                  64.2
  Study location (continent)[^\*^](#tfn_001){ref-type="table-fn"}                                                                              
   Asia                                                             304              38.4(36.5 to 40.3)               \<0.001                  95.6
   America (North and South)                                        81               24.4(22.1 to 26.8)               \<0.001                  96.8
   Europe                                                           62               14.1(12.7 to 15.5)               \<0.001                  87.3
  Study location (country)                                                                                                                     
   Japan                                                            107              36.6(33.2 to 40.0)               \<0.001                  96.4
   China                                                            104              38.4(35.7 to 41.1)               \<0.001                  93.0
   Korea                                                            48               32.4(28.0 to 36.8)               \<0.001                  94.8
   U.S.                                                             68               23.9(21.3 to 26.5)               \<0.001                  96.6
  Ethnicity                                                                                                                                    
   Caucasian                                                        96               17.4(15.8 to 18.9)               \<0.001                  92.0
   Asian                                                            301              38.8(36.8 to 40.8)               \<0.001                  95.8
   African-American                                                 5                17.2(5.7 to 28.8)                \<0.001                  89.0
   Mixed                                                            32               27.0(22.6 to 31.4)               \<0.001                  96.9
   Unclear                                                          22               19.3(16.4 to 22.2)               \<0.001                  94.3
  Gender                                                                                                                                       
   Male                                                             322              24.0(22.5 to 25.4)               \<0.001                  94.2
   Female                                                           331              43.7(41.5 to 45.9)               \<0.001                  94.8
  Smoking status                                                                                                                               
   Non-smoker                                                       284              49.3(47.2 to 51.4)               \<0.001                  91.5
   Past or current smoker                                           280              21.5(20.2 to 22.7)               \<0.001                  92.2
  Histology                                                                                                                                    
   Adenocarcinoma                                                   307              38.0(36.0 to 40.1)               \<0.001                  96.6
   Non-adenocarcinoma                                               203              11.7(10.6 to 12.7)               \<0.001                  83.6
  Stage                                                                                                                                        
   Stage I                                                          73               34.0(28.9 to 39.1)               \<0.001                  97.4
   Stage II                                                         55               29.9(25.0 to 34.7)               \<0.001                  84.9
   Stage III                                                        85               33.8(29.8 to 37.8)               \<0.001                  89.0
   Stage IV                                                         68               37.5(33.2 to 41.7)               \<0.001                  93.3
  Chemotherapy                                                                                                                                 
   Chemotherapy                                                     42               33.8(27.1 to 40.5)               \<0.001                  97.8
   No chemotherapy                                                  74               33.2(29.3 to 37.1)               \<0.001                  96.7

Legend: This table provides pooled prevalence and results from heterogeneity test of *EGFR* mutation in all eligible studies and different subgroups

Europe includes countries of the European Union and Norway, Switzerland, and Turkey; America includes Canada, the United States, Argentina, Brazil, Colombia, Mexico, and Peru; Asia includes China, East Asia, India, Japan, Korea, Malaysia, Singapore, Taiwan, and Thailand.

Many study or patient characteristics had little influence on *EGFR* mutation prevalence rates, including the disease stage at diagnosis, history of chemotherapy, mutation detection methods (post-hoc analysis of methods reported in 10+ studies) or year of study publication (post-hoc analysis) ([Table A.2](#SD1){ref-type="supplementary-material"} for post-hoc analysis).

Table [2](#T2){ref-type="table"} provides associations between of *EGFR* mutation prevalence and gender, smoking status, and tumor histology in Caucasian and Asian populations. Overall, prevalence was higher in females (females vs. males: 43.7% vs. 24.0%; OR: 2.7, 95% CI: 2.5 to 2.9) and the ORs did not differ significantly by ethnicity: Caucasian females vs. males OR 2.7, 95% CI 2.3 to 3.3; Asian females vs. males OR 2.8, 95% CI 2.6 to 3.1. The prevalence was also higher overall in non-smokers (non-smoker vs. past or current smoker: 49.3% vs. 21.5%; OR: 3.7, 95% CI: 3.4 to 4.0). Among non-smokers, as compared to past or current smokers, the mutation prevalence in Caucasians was greater than in Asians: Caucasian non-smokers vs. past or current smokers 39.8% vs. 10.8%; OR: 5.2, 95% CI: 4.4 to 6.3; Asian non-smokers vs. past or current smokers 52.2% vs. 26.3%; OR: 3.3, 95% CI: 2.9 to 3.6. NSCLC patients with adenocarcinoma were also far more likely to carry the *EGFR* mutation (adenocarcinoma vs. non-adenocarcinoma: 38.0% vs. 11.7%; OR: 4.1, 95% CI: 3.6 to 4.8) in overall participants. This observation was more striking in the Asian population (adenocarcinoma vs. non-adenocarcinoma: 44.7% vs. 12.5%; OR: 5.3, 95% CI: 4.4 to 6.4) than the Caucasian population (adenocarcinoma vs. non-adenocarcinoma: 19.7% vs. 9.6%; OR: 2.2, 95% CI: 1.7 to 2.7). The prevalence of *EGFR* mutation was not different in patients diagnosed at different NSCLC stages and by chemotherapy use history.

###### The association of *EGFR* mutation with gender, smoking status, and tumor histology in Caucasian and Asian populations

  Group variables            No. of studies   Mutation prevalence, 95%CI, (%)   Tests of heterogeneity   OR (95% CI)   
  -------------------------- ---------------- --------------------------------- ------------------------ ------------- -----------------
  **Caucasian population**                                                                                             
  Gender                                                                                                               
   Female                    66               25.0(22.4 to 27.7)                \<0.001                  87.2          2.7(2.3 to 3.3)
   Male                      62               10.1(8.6 to 11.5)                 \<0.001                  86.1          1.0
  Smoking status                                                                                                       
   Non-smoker                56               39.8(36.3 to 43.2)                \<0.001                  76.8          5.2(4.4 to 6.3)
   Past or current smoker    56               10.8(9.4 to 12.2)                 \<0.001                  82.9          1.0
  Histology                                                                                                            
   Adenocarcinoma            61               19.7(17.5 to 21.8)                \<0.001                  89.6          2.2(1.7 to 2.7)
   Non-adenocarcinoma        40               9.6(7.6 to 11.5)                  \<0.001                  84.1          1.0
  **Asian Population**                                                                                                 
  Gender                                                                                                               
   Female                    231              51.1(48.9 to 53.3)                \<0.001                  88.0          2.8(2.6 to 3.1)
   Male                      228              28.7(26.7 to 30.6)                \<0.001                  92.6          1.0
  Smoking status                                                                                                       
   Non-smoker                197              52.2(49.7 to 54.7)                \<0.001                  91.5          3.3(2.9 to 3.6)
   Past or current smoker    194              26.3(24.3 to 28.2)                \<0.001                  91.7          1.0
  Histology                                                                                                            
   Adenocarcinoma            214              44.7(42.4 to 47.0)                \<0.001                  93.8          5.3(4.4 to 6.4)
   Non-adenocarcinoma        144              12.5(11.1 to 13.9)                \<0.001                  84.0          1.0

Legend: This table provides pooled prevalence and results from heterogeneity test of *EGFR* mutation, and the pooled within-study ORs for the association between subgroup variables and *EGFR* mutation, in Caucasian populations and Asian populations respectively.

The prevalence trends in different patient groups remained when countries with at least of 50 studies were assessed separately (China, Japan, Korea and U.S) ([Table A.3](#SD1){ref-type="supplementary-material"} to [A.6](#SD1){ref-type="supplementary-material"}). Notable exceptions included a very low prevalence (3.3%, 95% CI: 2.4% to 4.1%) among patients with non-adenocarcinoma patients in Japan ([Table A.4](#SD1){ref-type="supplementary-material"}) and the higher prevalence for those who previously received chemotherapy in Japan (45.3%, 95% CI: 37.7% to 52.8%) and Korea (34.8%, 95% CI: 18.4% to 51.2%) ([Tables A.4 and A.5](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#s3}
==========

In this study, we found that approximately one-third of NSCLC patients harbor an *EGFR* mutation. Patients who are Asian, female, non-smokers, and have adenocarcinoma are more likely to harbor an *EGFR* mutation, which is consistent with previous studies \[[@R23], [@R29], [@R31]--[@R33]\].

Some previous systematic reviews were published reporting the prevalence of *EGFR* mutation in patients with non-small cell lung cancer \[[@R34]--[@R38]\]. These previously published work focused on patient subgroups such as smokers, adenocarcinomas or studies only in Chinese population. Moreover, all these previous reviews did not employ meta-analysis method to pool the prevalence from original studies. Despite of these difference, the pooled prevalence estimates we generated were similar to these smaller systematic reviews. The overall pooled prevalence in our study is similar to some existing large individual studies, though there is considerable variation among countries and individual studies may not be relied upon for accurate prevalence rates \[[@R39]--[@R41]\]. Individual study divergence from the pooled estimates likely reflects the patient characteristics within studies. *EGFR* mutation prevalence is clearly influenced by these characteristics and thus, this large review of whole populations and subgroups provides the best evidence for *EGFR* mutation prevalence \[[@R42], [@R43]\].

Recent clinical guidelines from the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) recommend all patients with advanced or metastatic non-squamous NSCLC to receive *EGFR* mutation testing \[[@R2], [@R44]\]. A cost-effectiveness analysis also supports mutation testing vs. no testing for eligibility of second-line gefitinib treatment, after the failure of platinum-containing doublet \[[@R45]\]. However, this may require substantial resources and effort and at present, the cost of *EGFR* mutation testing in some countries is met by patients\' out-of-pocket expenses or from research funds, and can vary from U.S.\$ 150 to several hundred U.S.\$ \[[@R46]\]. Although non-invasive genetic testing methods exist \[[@R47]\], mutation detection using tumor tissues is still the gold standard for *EGFR* mutation testing. Such barriers prevent the widespread use of *EGFR* mutation testing and testing rates likely reflect the level of health service development and insurance coverage. *EGFR* mutation testing rates in NSCLC vary considerably among countries with approximately 9.6% in Chinese metropolitan areas in 2010 \[[@R48]\] and approximately 39.5% and 53.9% of patients in Korea and Japan, respectively \[[@R49], [@R50]\]. Where full coverage of screening is not available or possible, providers may target the patient groups identified in this review who are more likely to harbor mutations (e.g. 51.5% of Asian females, 52.2% of Asian smokers, 44.7% of Asian patients with adenocarcinoma, and 39.8% of Caucasian non-smokers harbor an *EGFR* mutation). Although *EGFR* mutation prevalence in some populations is relatively low at about 10% (e.g. 10.1% in Caucasian males and 12.5% in Asian patients with non-adenocarcinoma) screening must still be provided and only be targeted in resource limited settings. Given the fact that the efficacy of standard chemotherapy for patients with NSCLC remains limited, universal testing for *EGFR* mutation may improve overall prognosis through the early use of first-line EGFR-TKI treatment.

A major strength of this work is the large number and range of studies included to estimate the prevalence of *EGFR* mutation in different NSCLC patient groups. These estimates can serve as the reference for the future research or policy making. However, several limitations of our study need to be mentioned. Firstly, since patients with higher likelihood of harboring an *EGFR* mutation are more likely to be tested, the overall prevalence may be overestimated. However, detailed recruitment information was not provided in many studies so we could not assess the influence of selection bias. Secondly, lack of relevant studies prevented us from further exploring the prevalence of *EGFR* mutation in some patient subgroups, such as Asian female non-smokers and Asian female adenocarcinoma patients. Thirdly, significant heterogeneity was found among included studies in almost all the analyses, which seems common in meta-analysis of single arm studies. The substantial difference in patient characteristics, clinical settings, and research methodologies among eligible studies may contribute to the high level of heterogeneity. Unfortunately, without individual patient data it is not possible to further sub-divide prevalence estimates for precise patient groups such as women in the U.S. who are non-smokers and have adenocarcinoma. Despite noted limitations, we believe that this comprehensive synthesis of existing available studies provides valuable estimates of *EGFR* mutation prevalence.

This systematic review and meta-analysis estimates the prevalence of *EGFR* mutations in NSCLC patient subgroups. *EGFR* mutation prevalence estimates in these subgroups can inform policy makers of those patients who are more likely to benefit from EGFR-TKI treatment.

MATERIALS AND METHODS {#s4}
=====================

Data sources and search strategy {#s4_1}
--------------------------------

We performed a comprehensive literature search in PubMed, EMBASE, and Cochrane Library from their respective inception to June 2013, with different combinations of the following keywords: "EGFR", "lung cancer", and "mutation". The literature search was restricted to human studies. No language restriction was applied. We manually checked reference lists of the included studies and relevant reviews to identify additional studies. Details of the search strategy are summarized in [Table A.7](#SD1){ref-type="supplementary-material"}.

Study selection {#s4_2}
---------------

Studies reporting the prevalence of *EGFR* mutation and odds ratio (OR) to estimate the association of *EGFR* mutation with at least one of the following factors (gender, smoking status, and histology) in patients with NSCLC were considered eligible. For duplicate publications, we selected the most recent and complete version of publications. Two reviewers (WKF and YJQ) independently assessed the study eligibility. Any discrepancies were resolved by consensus or by consulting with a third reviewer (MC).

Data extraction {#s4_3}
---------------

Data extraction was performed independently by two reviewers (WKF and YJQ). Disagreements were resolved by discussion between the two. If no agreement was reached, then a third researcher (MC) was invited to resolve the disagreement. The following data were collected from each study using a predefined data extraction form: study characteristics (such as the first author\'s name, year of publication, study location, study design, and sample size), patient characteristics (such as proportion of females, proportion of non-smokers, and proportion of adenocarcinoma), and the prevalence of *EGFR* mutation (such as the number of patients with *EGFR* mutation and OR for association of *EGFR* mutation with gender, smoking status, and histology).

Outcome measure and subgroup variables {#s4_4}
--------------------------------------

We defined the primary outcome of interest in this systematic review as *EGFR* mutation. The prevalence of *EGFR* mutation was defined as the proportion of patients with *EGFR* mutation among patients who received the mutation testing. Study location was determined using the place where the patients were recruited in the study. If the authors did not describe the patient recruitment, the affiliation address of the corresponding author was used to identify the study location. Population ethnicity was divided into Caucasian, Asian, African-American, and mixed ethnicities. Ethnicity classification was based on the information in the original publication or the principle ethnicity of each country, where the detailed information was not reported (e.g. Italy = Caucasian, Japan = Asian). Similarly, the classifications of smoking status, tumor histology, tumor stage, and previous use of chemotherapy were defined according to the information in original publications.

Data analysis {#s4_5}
-------------

We conducted meta-analysis to pool the prevalence of *EGFR* mutation in different NSCLC patient groups. Subgroup analyses were performed according to the following factors: *EGFR* exons (exon 19, 21 or both, and the others), study locations (at least 50 studies in each location), ethnicity, gender, smoking status (non-smoker or past or current smoker), tumor histology (adenocarcinoma or non-adenocarcinoma), tumor stage, and previous use of chemotherapy. The within-study OR was combined to estimate the association of *EGFR* mutation with gender, smoking status, and tumor histology. Post-hoc subgroup analysis was conducted according to the detection methods of *EGFR* mutation, types of samples used in the detection, and the publication year of the study. Given the diverse nature of studies and the likely heterogeneity, we applied random-effects models to carry out meta-analysis by the Der-Simonian Laird method \[[@R51]\]. The statistical heterogeneity among the studies was assessed by the Cochran\'s Q-test and the I^2^ statistic. A P value ≤ 0.10 for the Cochran\'s Q-test or an I^2^ ≥ 50% was suggestive of significant among-study heterogeneity. We used Stata 12.0 (StataCorp, College Station, TX) to conduct all the analyses with a two-tailed significance level of 0.05 except in the assessment of heterogeneity (α = 0.10).
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